


# *Structures for a new era of drug discovery*

Jonathan Mullins

Genome and Structural Bioinformatics, ILS, Swansea University Medical School

Founder and CEO, Moleculomics Ltd

11<sup>th</sup> February 2016







# What We Do



# What We Do

## Genome / Multi-Genome Scale :

- Structural modelling at vast scales
- Affinity docking of vast compound libraries “Rapid *in silico* exploration”
- Pharmacological profiling and toxicity screening, precision medicine
- Prediction of protein-protein interactions and networks
- *In silico* pathway analysis
- Comparative structural proteomics



# Partners - Projects - Products

TargetPath - a lead discovery platform for antibiotics



Host-Pathogen Interactomes



Centre for Defence Enterprise

*In silico* pharmacological profiling panel



Unilever

*In silico* toxicity screening panel



# Partners - Projects - Products

In silico analysis of pipeline drug compounds



Pharmacological profiling of Brazilian natural compounds



Tumour-specific cancer drug targets based on exome sequences





International  
Cancer Genome  
Consortium



# What Makes Us Different.....

- R&D based on a track record of 50+ journal publications
- Validated workflows in partnership with target industries

*“Moleculomics is the only company offering structurally-based open-ended lead discovery, toxicity screening and protein network identification, that is completely unlimited in reach, applied across the entire proteome.”*



[j.g.l.mullins@swansea.ac.uk](mailto:j.g.l.mullins@swansea.ac.uk)





Dow AgroSciences



CompTIA



Swansea University  
Prifysgol Abertawe



Technology Strategy Board  
Driving Innovation



Centre for Defence Enterprise



MONTRÉAL  
INTERNATIONAL



SOFTWARE  
ALLIANCE  
WALES



CYNGHRAIR  
MEDDALWEDD  
CYMRU



Llywodraeth Cymru  
Welsh Government



CQIB  
L'incubateur  
des sciences de la vie